Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Boehringer provides update on iclepertin Phase III program in schizophrenia
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not met. 1–6 Overall, no statistically significant effects on cognition or functioning were observed in patients treated with iclepertin versus placebo at six months. 1 All three trials demonstrated that iclepertin, a glycine transporter 1 (GlyT1) inhibitor, was generally well tolerated, with a...
Nasdaq GlobeNewswire
16/01/2025
Pellet Heating Stoves Market to Reach USD 726.1 Million by 2030 | Residential…
Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-30X8823/Global_Pellet_Heating_Stoves_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-30X8823/Global_Pellet_Heating_Stoves_Market Major Factors Driving the Growth of Pellet Heating Stove Market Pellet heating stoves play a crucial role in maintaining optimal temperature conditions for the storage and transportation of perishable goods, ensuring product quality and...
PR Newswire
16/01/2025
King Faisal Specialist Hospital and Research Centre Performs the World's First…
RIYADH, Saudi Arabia, Jan.16, 2025(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world's first robotic-assisted implantation of an artificial heart pump (HeartMate 3) developed by Abbott, a groundbreaking procedure that marks a significant advancement in medical technology and patient care.The surgery was performed on a 35-year-old man who had been hospitalized for 120 days due to advanced heart failure, which...
Nasdaq GlobeNewswire
16/01/2025
Zero Candida Announces Successful Listing on Frankfurt Stock Exchange and…
The Frankfurt Stock Exchange (FSE), operated by Deutsche Börse AG, is one of the world's leading trading venues for securities and Germany's largest stock exchange. THE FSE is recognized for its efficiency and transparency with electronic trading and settlement, enabling smooth cross-border transactions for international investors. The listing on the FSE provides Zero Candida with a strategic opportunity to connect with international investors and further establish its presence in Europe and…
PR Newswire
16/01/2025
Kindeva Drug Delivery awarded up to $129 million to supply DuoDote®…
Kindeva manufactures DuoDote® in the U.S. for distribution at strategic locations across the U.S. as part of the country's emergency preparedness program to protect civilians from chemical nerve agent attacks. The treatment will be stockpiled and available for rapid deployment as part of the SNS CHEMPACK program. Kindeva manufactures DuoDote® in the U.S. for distribution at strategic locations across the U.S. as part of the country's emergency preparedness program to protect civilians from...
PR Newswire
16/01/2025
New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to…
"No other landscape in medicine has changed as drastically as the field of clinical genetics," said Mary B. Daly, MD, PhD, FACP, Fox Chase Cancer Center; and Chair of the NCCN Guidelines® Panel for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. "The changes have been facilitated by the work of the Human Genome Project but have gone way beyond its scope. Advances in technology have been a major driver of the explosion of knowledge in genetics, now…
PR Newswire
16/01/2025
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market…
Data from proof-of-concept studies of DPX-mRNA formulations conducted in collaboration with leading RNA technology company Etherna and PCI Biotech demonstrate that DPX provides enhanced in vitro and in vivo stability of packaged mRNA, attracts a therapeutically unique subset of Antigen Presenting Cells (APCs) to the injection site for targeted uptake of mRNA by the immune system, and that immunization with DPX containing mRNA induces specific immune responses towards encoded antigens. Data...
PR Newswire
16/01/2025
Aescuvest Capital Partners (ACP) Fund Empowers Visionary Healthtech Innovators…
"Our mission extends beyond financial gains; we aim to support companies that will transform healthcare delivery," said Christoph Bartoschek, ACP's Investment Principal. With a strong background in healthcare finance and strategic investments, Bartoschek utilizes ACP's extensive network and regulatory insights to expedite approval processes, ensuring portfolio companies achieve critical milestones efficiently. "Our strategic partnerships and regulatory expertise give us a…
PR Newswire
16/01/2025
KFSHRC Launches Precision Medicine Services in Family Medicine Clinics to…
The launch of this service marks a significant shift in patient and family care, transitioning from a generalized approach to diagnosis and treatment to a more specific and precise method. This approach is built on analysing genetic codes and linking the results to lifestyle, medical history, and the genetic data of other family members. This enables the development of preventive and therapeutic plans tailored to each patient's unique needs, in addition to facilitating early disease...
Nasdaq GlobeNewswire
16/01/2025
Hurom Secures Victory in Korea Trade Commission Case Against NUC (Kuvings)
On December 19, 2024, the KTC ruled that NUC had infringed Hurom's patent rights, constituting unfair trade practices. The KTC issued a corrective order, imposed fines, and formally notified NUC of its decision. OnDecember 19, 2024, the KTC ruled that NUC had infringed Hurom's patent rights, constituting unfair trade practices. The KTC issued a corrective order, imposed fines, and formally notified NUC of its decision. The investigation began inDecember 2023when Hurom filed a...
PR Newswire
16/01/2025
BioWorld by Clarivate Releases Comprehensive 2024 Year in Review
As the biopharma and med-tech industries continue to evolve, 2024 proved to be a landmark year. The comprehensive recap by BioWorld highlights therapeutic breakthroughs in psychiatry, oncology, women's health and infectious diseases, alongside economic highs and lows that challenged the global landscape. The series also examines regulatory changes, including U.S. court cases and international policy shifts, that could shape the future of drug pricing, reimbursement, and innovation. As the...
PR Newswire
16/01/2025
SKF to publish Q4 report on 31 January
To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers: To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers: Link to web event:https://www.investis-live.com/skf/675823f083fc4b000e12bc0e/pakvt Sweden : +46 8 5051 0031 UK / International: +44 207 107 0613 All information regarding the results will be made available on the Group's IR website:...
PR Newswire
16/01/2025
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE®…
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in relation to AGAMREE® (vamorolone). Idorsia has also recently exercised outstanding warrants held in Santhera on a cashless basis, reinforcing its position as a major shareholder in the Company.Idorsia transfers rights to royalties and milestones for AGAMREE (vamorolone) to R-Bridge...
Nasdaq GlobeNewswire
16/01/2025
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a…
Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarter Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends AGAMREE® (vamorolone) for use in the National Health Service (NHS) in England, Wales and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of...
Nasdaq GlobeNewswire
16/01/2025
KFSH&RC Celebrates 25 Scientists Named in Stanford's Top 2% Most-Cited…
RIYADH, Saudia Arabia, Jan.16, 2025(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre honored 25 scientists who joined Stanford University's prestigious list, marking them among the 'top 2% most-cited scientists' list updated in October 2023.The recent release recognizes 25 distinguished KFSH&RC scientists, among the top 2% most-cited researchers worldwide in 2021-2022, and acknowledges their overall career accomplishments. This prestigious recognition...
Nasdaq GlobeNewswire
16/01/2025
Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create…
Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will be available for replay on demandAllschwil, Switzerland – January 15, 2025Idorsia Ltd (SIX: IDIA) today announced that André C. Muller, Chief Executive Officer of Idorsia, will present at the J.P. Morgan Healthcare Conference on January 15, 2025, at 15:00 PST / 00:00 CET. The conference will take place at the Westin St. Francis hotel in San Francisco, USA...
Nasdaq GlobeNewswire
15/01/2025
Acute Coronary Syndrome Market to Showcase a Significant Growth at a CAGR of…
Key Takeaways from the Acute Coronary Syndrome Market Report Key Takeaways from the Acute Coronary Syndrome Market Report Discover which therapies are expected to grab the major acute coronary syndrome market share @ Acute Coronary Syndrome Market Report Acute Coronary Syndrome Overview Acute coronary syndrome (ACS) is a term used to describe a range of conditions resulting from the sudden reduction or interruption of blood flow to the heart. This condition is often caused by...
PR Newswire
15/01/2025
Sanofi: Information concerning the total number of voting rights and shares –…
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,537,214,304 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
15/01/2025
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…
Disclosure of Share Capital and Voting Rights Outstandingas of December 31, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (January 15, 2025 - 6:00 pm)– As of December 31, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down...
Nasdaq GlobeNewswire
15/01/2025
Groupe Casino - Nombre de droits de vote et d'actions 31-12-2024
CASINO, GUICHARD-PERRACHON Société anonyme au capital de 4 009 397,13 € Siège social : 1, Cours Antoine Guichard 42000 Saint-Etienne 554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 31 décembre 2024(article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) Nombre d'actions composant le capitalNombre total de droits de voteNombre total de droits de vote ...
Nasdaq GlobeNewswire
15/01/2025
Inside information: Orion upgrades full-year outlook for 2024 and provides…
ORION CORPORATIONSTOCK EXCHANGE RELEASE – INSIDE INFORMATION 15 JANUARY 2025 at 18:25 EET Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit because product sales, Nubeqa® royalty income and excellent supply service level have continued to grow net sales faster than expected...
Nasdaq GlobeNewswire
15/01/2025
Global Turbo Chiller Market Analysis: Water-Cooled and Air-Cooled Turbo Chillers…
Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-33Y7020/Global_Turbo_Chiller_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-33Y7020/Global_Turbo_Chiller_Market Major Factors Driving the Growth of Turbo Chiller Market: The Turbo Chiller market is set for significant growth, driven by the increasing demand for efficient and reliable cooling solutions across diverse industries such as data centers, manufacturing,...
PR Newswire
15/01/2025
Cerebrospinal Fluid (CSF) Management Market Set to Reach USD 3.8 Billion by…
Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1038984 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1038984 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Cerebrospinal Fluid (CSF) Management Market Overview Market Size and Growth The global Cerebrospinal Fluid (CSF) Management Market is projected to grow significantly, reachingUSD 3.8 billionby 2031 fromUSD 2...
PR Newswire
15/01/2025
Artificial Intelligence (AI) in Medical Imaging Market to Hit USD 4.54 Billion…
Browse in-depth TOC on "Artificial Intelligence (AI) in Medical Imaging Market" Browse in-depth TOC on "Artificial Intelligence (AI) in Medical Imaging Market" 400 - Tables176 - Figures500 - Pages However, there are challenges in the form of a shortage of skilled AI professionals and ambiguous regulatory frameworks that are expected to slow growth to some extent. Based on components, the market is segmented into software, services, and hardware. The software segment...
PR Newswire
15/01/2025
Altri Comunicati
